Last update Aug. 19, 2021
Likely Compatibility
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
(1-Thio-β-d-glucopyranosato)(triethylphosphine)gold 2,3,4,6-tetra-acetate is Auranofin in Chemical name.
Is written in other languages:(1-Thio-β-d-glucopyranosato)(triethylphosphine)gold 2,3,4,6-tetra-acetate belongs to this group or family:
Main tradenames from several countries containing (1-Thio-β-d-glucopyranosato)(triethylphosphine)gold 2,3,4,6-tetra-acetate in its composition:
Variable | Value | Unit |
---|---|---|
Oral Bioavail. | 25 | % |
Molecular weight | 679 | daltons |
Protein Binding | 60 | % |
Tmax | 1.5 -2.5 | hours |
T½ | 408 - 1939 | hours |
Write us at elactancia.org@gmail.com
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2015 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
Gold compound with anti-inflammatory properties. Other similar compounds are aurothiomalate and aurothioglucose.
Used as a disease-modifying antirheumatic drug (DMARD) in active rheumatoid arthritis and psoriatic arthritis.
Oral administration once or twice a day.
At the date of the last update, the authors did not find any published data on its excretion in breast milk.
Its pharmacokinetic data (low protein binding and very long half-life) make it probable that it will pass into breast milk in an amount that could be significant.
Until more published data is known about this drug in relation to breastfeeding, alternatives with a known safer pharmacokinetic profile for breastfeeding may be preferable, especially during the neonatal period and in the event of prematurity.
Expert authors consider the use of gold salts during lactation to be low risk (Ostensen 1992, Needs 1985). Other authors believe that they best be avoided during breastfeeding (Janssen 2000, Byron 1987, Ostensen 1986).
American Academy of Pediatrics: Gold salts are medications usually compatible with breastfeeding (AAP 2001).
See below the information of this related product: